Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
5.69
+0.06 (1.07%)
Aug 22, 2025, 4:00 PM - Market closed
Immatics Employees
As of December 31, 2024, Immatics had 682 total employees, including 554 full-time and 128 part-time employees. The number of employees increased by 147 or 27.48% compared to the previous year.
Employees
682
Change (1Y)
147
Growth (1Y)
27.48%
Revenue / Employee
$224,081
Profits / Employee
-$128,724
Market Cap
691.67M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 682 | 147 | 27.48% |
Dec 31, 2023 | 535 | 93 | 21.04% |
Dec 31, 2022 | 442 | 61 | 16.01% |
Dec 31, 2021 | 381 | 98 | 34.63% |
Dec 31, 2020 | 283 | 56 | 24.67% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMTX News
- 10 days ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma - GlobeNewsWire
- 3 months ago - Immatics Announces First Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 4 months ago - Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting - GlobeNewsWire
- 5 months ago - Immatics N.V.: Trading Below Cash, But Not Without Reason - Seeking Alpha
- 5 months ago - Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewsWire
- 9 months ago - Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME - GlobeNewsWire
- 10 months ago - Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME - GlobeNewsWire